PDSB - PDS Biotech to Participate in Upcoming May 2024 Investor Conferences | Benzinga
PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will participate in two upcoming investor conferences taking place in May 2024. Details are as follows:
The Citizens JMP Life Sciences Conference
Event: Company presentation and 1:1 meetings
Presentation Date and Time: Monday, May 13, 2024, 12:30 PM ET
Location: New York Hilton Midtown, New York, NY
To register for the presentation, click here. Please contact your Citizens JMP representative to schedule a 1:1 meeting with PDS Biotech.
A.G.P.'s Virtual Healthcare Company Showcase
Event: Fireside chat with A.G.P.'s Jim Molloy and Scott Henry
Fireside Chat Date and Time: Tuesday, May 21, 2024, 10:00 AM ET
To register, please click here.
Following the event, an archived replay of the fireside chat will be available in the Investor Relations section of the Company's website at www.pdsbiotech.com.
About PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines. The Company plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced head and neck squamous cell cancers (HNSCC). PDS Biotech's lead program is a proprietary dual-acting combination of IL-12 fused antibody drug conjugate (ADC) PDS01ADC and T-cell activator Versamune® HPV in regimen with a standard-of-care immune checkpoint inhibitor. We believe that proof-of-concept long-term data have shown positive survival results and tumor shrinkage with this combination and indicate favorable tolerability.
We believe that with a novel investigational "inside-outside" mechanism, the PDS01ADC and Versamune® HPV immunotherapy has shown compelling results with potential to successfully disrupt a tumor's inside defenses, while also generating potent, targeted killer T-cells to attack the tumor from the outside. We believe that data from more than ...